what are the risks of glp 1 drugs Nutritional Side Effects GLP-1 Drugs: Deficiencies, Muscle Loss, and to Monitor Friday Shorts: GLP-1, HPV and

Stuart Phillips is a professor of Kinesiology and the Tier 1 Canada Research Chair in Skeletal Muscle Health

Food and Drug Administrations (FDAs) patient-focused drug development initiative

The SUSTAIN-7 trial was a randomized, open-label, active-controlled, parallel, four-armed trial

For where these oral and higher-dose options sit among the candidates now in development, see the 2026 GLP-1 clinical pipeline, part of the broader GLP-1 and metabolic disease picture

The compound appears to act as both a substrate and inhibitor of these enzymes, which metabolize numerous medications

Galluzzi L, Vacchelli E, Michels J, et al